Interventions for CKD-Associated Cardiomyopathy.

SpringerLink

880-01 Foreword; Preface; Contents; Contributors; Cardiovascular Disease Spectrum in Chronic Kidney Disease; 1 Endothelial Dysfunction and Nitric Oxide: Albuminuria as a Central Marker; Endothelial Function; Endothelial Activation and Endothelial Dysfunction; Evaluation of Endothelial Dysfunction; Nitric Oxide and Endothelium; Albuminuria and Endothelium; Albuminuria and Cardiovascular Disease; Summary; References; 2 Vascular and Valvular Calcification in Chronic Kidney Disease: Pathogenesis and Clinical Outcomes; Introduction; Vascular Calcification; Valvular Calcification.

4 Coronary Artery Disease in CKD: Traditional and Nontraditional Risk Factors, Diagnosis and ManagementEpidemiology of CAD in CKD Patients; Pathophysiology; Traditional and Nontraditional Risk Factors; Clinical Presentation; Reduction of CAD Risk in CKD Patients; Medical Therapy; Statins; Blood Pressure Management; Antiplatelet Therapy; Revascularization in CKD Patients; Stable Angina; STEMI and NSTEMI; CABG Versus PCI in CKD Patients; References; 5 CKD Associated Cardiomyopathy: Molecular Mechanisms, Imaging Modalities, Disease Evolution and Interventions; Introduction; Molecular Mechanisms.

Pathogenesis of Vascular CalcificationPathogenesis of Valvular Calcification; Pathogenesis of Vascular and Valvular Calcification in CKD and ESKD; Disturbance in Mineral Metabolism; Alteration in Inhibitory Regulation; Increase in Matrix Metalloproteinases (MMP); Chronic Inflammation; Mechanical Stress; Clinical Impact of Vascular Calcification; Medical Strategies to Prevent Calcification; Clinical Impact of Valvular Calcification; Aortic Valve; Mitral Valve; Conclusion; Disclosures; References; 3 Sudden Cardiac Death in CKD and ESKD: Risk Factors, Mechanisms, and Therapeutic Strategies.

Renin-Angiotensin-Aldosterone System (RAAS)Abnormal Calcium and Phosphate Metabolism; Phosphate; Fibroblast Growth Factor 23 (FGF-23); Parathyroid Hormone; Vitamin D; Hyperuricemia; Protein Bound Uremic Toxins; Cardiotonic Steroids; Insulin Resistance; Imaging Modalities in CKD-Associated Cardiomyopathy; Left Ventricular Mass; Myocardial Fibrosis; Late Enhancement Imaging; T1 Mapping; Gadolinium-Based Contrast Agents in CKD; Computed Tomography; Cardiac Magnetic Resonance as the Proposed Imaging Modality of Choice in CKD; Evolution of CKD-Associated Cardiomyopathy.

Extending from the outpatient management of cardiovascular and kidney disease, to hospital-based decision making in patients with cardio-renal disease and complex interfaces such as hemodialysis in patients with ventricular assist device support, this book serves as a single reference point for cardiology and nephrology clinicians and researchers dealing with the significant overlap areas between these two specialties. Chapters cover the physiology, biomarkers, therapeutic agents and full spectrum of these comorbidities and feature separate sections on cardiovascular and CKD evaluations, stratification of kidney transplant patients, lipid management in CKD, interventional strategies and hypertension. Leaders in cardiology, nephrology, hypertension and lipidology bring together the latest evidence with their collective clinical experience into this invaluable resource. This textbook is an essential resource for physicians and allied professionals practicing cardiology, nephrology, students and physician trainees, to deepen their understanding of this crucial field.